Literature DB >> 15830293

Pediatric nonalcoholic steatohepatitis associated with hypopituitarism.

Kenichirou Nakajima1, Etsuko Hashimoto, Hiroyuki Kaneda, Katsutoshi Tokushige, Keiko Shiratori, Naomi Hizuka, Kazue Takano.   

Abstract

We experienced two cases of pediatric nonalcoholic steatohepatitis (NASH) associated with hypopituitarism. The first patient was diagnosed with a craniopharyngioma at 5 years of age. After an operation to treat the condition, the patient gradually became obese, and an elevation of transaminases was observed. At 16 years of age, the patient was diagnosed as having NASH with liver cirrhosis. He was started on hormone replacement therapy; however, his insulin resistance and liver fibrosis, as evaluated by hyaluronic acid and platelet count, progressed. In addition, his hyperleptinemia continued. The second patient was diagnosed, at 10 years of age, as having pituitary dysfunction due to fetal asphyxia, and he was started on hormone replacement therapy. This patient was noted to have been obese throughout his life. He was diagnosed as having NASH with advanced fibrosis at 18 years of age. It is important for both hepatologists and endocrinologists to be aware of the association between pituitary dysfunction and NASH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15830293     DOI: 10.1007/s00535-004-1541-4

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

Review 1.  Epidemiology of Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Elizabeth L Yu; Jeffrey B Schwimmer
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

2.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

3.  The Way to the Liver Is Through the Pituitary Gland.

Authors:  Ashraf A Ashhab; Jeffrey Albrecht; Jose D Debes
Journal:  Am J Gastroenterol       Date:  2018-01       Impact factor: 10.864

Review 4.  Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature.

Authors:  Masafumi Ono; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

5.  Diagnosis and treatment of pediatric nonalcoholic steatohepatitis and the implications for bariatric surgery.

Authors:  Perrie E Pardee; Joel E Lavine; Jeffrey B Schwimmer
Journal:  Semin Pediatr Surg       Date:  2009-08       Impact factor: 2.754

6.  [Non-alcoholic steatohepatitis and cirrhosis in young adult patients with hypothalamic-pituitary dysfunction].

Authors:  D Goltz; K Schötta; H Zhou; H-P Fischer
Journal:  Pathologe       Date:  2013-07       Impact factor: 1.011

7.  Nonalcoholic Fatty liver disease and metabolic syndrome in hypopituitary patients.

Authors:  Ebenezer A Nyenwe; Sarah Williamson-Baddorf; Bradford Waters; Jim Y Wan; Solomon S Solomon
Journal:  Am J Med Sci       Date:  2009-09       Impact factor: 2.378

8.  Hepatopathy in an adult, secondary to congenital untreated panhypopituitarism and ectopic posterior pituitary gland.

Authors:  Miguel A Valle-Murillo; Ivan Perez-Diaz
Journal:  Indian J Endocrinol Metab       Date:  2012-09

9.  Panhypopituitarism due to Absence of the Pituitary Stalk: A Rare Aetiology of Liver Cirrhosis.

Authors:  Marta Gonzalez Rozas; Lidia Hernanz Roman; Diego Gonzalez Gonzalez; José Luis Pérez-Castrillón
Journal:  Case Rep Endocrinol       Date:  2016-04-24

10.  Effects of recombinant human growth hormone administration on cardiovascular risk factors in obese children with relative growth hormone deficiency.

Authors:  Shuang Liang; Jiang Xue; Guimei Li
Journal:  Lipids Health Dis       Date:  2018-04-03       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.